Answers are grounded in this paper and cite their sources.
Innate immunity is the first defense against pathogens, sterile injury, and homeostatic perturbations. One key mechanism used by the innate immune system for host defense is inflammatory cell death, PANoptosis, which eliminates infected or damaged cells and releases cytokines and other danger signals that can further propagate the immune response. Given these inflammatory functions, PANoptosis must be tightly regulated to prevent excess inflammation and pathology. Cellular metabolism is a key regulator of innate immunity, yet how metabolic reprogramming regulates innate immune signaling to control cell death, inflammation, and disease remains poorly understood. Here, we identify the immune-responsive gene 1 (IRG1)-itaconate axis as a critical regulator of PANoptosis. Innate immune triggers robustly induced IRG1 expression, leading to itaconate accumulation and driving IRG1-dependent inflammatory cell death. Mechanistically, glutaminolysis fueled IRG1-dependent itaconate synthesis, and inhibition of glutamine metabolism reduced itaconate accumulation and blocked PANoptosis. Furthermore, NAD⁺ depletion, a known inducer of NLRC5-mediated PANoptosis that has been connected to hemolytic, infectious, and inflammatory conditions, acted upstream inducing IRG1 expression and promoting NLRC5-PANoptosome assembly. Together, these findings highlight IRG1 as a metabolic node linking innate immunity to PANoptosis, identifying IRG1 as a potential therapeutic target in hemolytic and inflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Pandian et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: